Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer—Does pT0 Predict Better Survival than pTa/Tis/T1?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer—Does pT0 Predict Better Survival than pTa/Tis/T1?

Published:2016-04 Issue:4 Part 1 Volume:195 Page:886-893
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Zargar Homayoun¹,Zargar-Shoshtari Kamran²,Lotan Yair³,Shah Jay B.⁴,van Rhijn Bas W.⁵,Daneshmand Siamak⁶,Spiess Philippe E.²,Black Peter¹,

Affiliation:

1. Vancouver Prostate Centre, Vancouver, British Columbia, Canada

2. Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

3. Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas

4. Department of Urology, MD Anderson Cancer Center, Houston, Texas

5. Department of Urology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

6. USC/Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, California

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference11 articles.

1. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines;Witjes;Eur Urol,2014

2. NCCN Guidelines for Bladder Cancer Version 1.2015. Available at https://www.nccn.org/.

3. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer;Grossman;N Engl J Med,2003

4. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis;Petrelli;Eur Urol,2014

5. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma;Van Allen;Cancer Discov,2014

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer;Clinical Genitourinary Cancer;2024-10

2. Biomarker challenges in the pursuit of personalized neoadjuvant chemotherapy for muscle-invasive bladder cancer: conclusions from SWOG S1314;Translational Andrology and Urology;2024-03

3. Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group;Journal of Clinical Oncology;2023-12-10

4. HER2 overexpression predicts pathological T2 stage and improved survival in de novo muscle-invasive bladder cancer after immediate radical cystectomy: A retrospective cohort study;International Journal of Surgery;2023-11-02

5. Does Bladder Cancer Subtype Influence Pathologic Complete Response (pCR) and Pelvic Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Response Evaluation After Neoadjuvant Chemotherapy? Pathological Perspective;Clinical Genitourinary Cancer;2023-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3